Also found in: Dictionary, Wikipedia.

dornase alfa


Pharmacologic class: Recombinant human deoxyribonuclease I

Therapeutic class: Cystic fibrosis agent, mucolytic enzyme, respiratory inhalant

Pregnancy risk category B


Selectively cleaves to DNA in sputum, decreasing viscosity of pulmonary secretions


Inhalation solution: 2.5-mg ampule (1 mg/ml)

Indications and dosages

To reduce respiratory tract infections and improve pulmonary function in patients with cystic fibrosis

Adults and children: One ampule (2.5 mg) inhaled once daily; some patients may benefit from twice-daily dosing. Safety and efficacy of daily administration haven't been demonstrated for longer than 12 months.


• Hypersensitivity to drug, its components, or products derived from Chinese hamster ovary cells


Use cautiously in:

• pregnant or breastfeeding patients.


• Don't shake, dilute, or mix with other drugs.

• Use only with approved nebulizer.

• Discard cloudy or discolored solution.

Adverse reactions

CV: chest pain

EENT: conjunctivitis, rhinitis, pharyngitis, hemoptysis, voice changes

Respiratory: dyspnea, increased sputum, wheezing

Skin: rash, urticaria, pruritus

Other: hypersensitivity reactions


None known

Patient monitoring

• Assess patient periodically. Report improvement in dyspnea and sputum clearance.

• Monitor for signs and symptoms of hypersensitivity reaction.

Patient teaching

• Teach patient how to use nebulizer.

• Instruct patient to report rash, hives, and itching.

• As appropriate, review all other significant adverse reactions mentioned above.


(po͝ol′mə-zīm′, pŭl′-)
A trademark for the drug dornase alfa.


Dornase alpha solution Pulmonology A therapy for cystic fibrosis for FVC–forced expiratory volume < 40% to improve pulmonary function and ↓ RTIs requiring parenteral antibiotics. See Cystic fibrosis.


A brand name for DORNASE ALFA.
References in periodicals archive ?
Some people with CF will benefit from taking both Bronchitol and Pulmozyme in combination.
Consensus conference: practical applications of Pulmozyme.
Both groups of patients given the Pulmozyme had significant reduction in the number of patients needing antibiotics for respiratory tract infections compared to the placebo group.
Kirk Raab, Genentech's CEO, is more direct: "I don't think we would have developed Pulmozyme if the Clinton price controls had been imposed.
The cost of these drugs is generally quite high; for example, Pulmozyme, for the treatment of cystic fibrosis, is approximately $10,000 per year.
JHL Biotech is developing JHL1922, a proposed similar biological product to dornase alfa which has the brand name Pulmozyme in the European Union (EU) and in the United States (US).
It was hoped that the study would prove the treatment is more effective than its rival product, Roche's Pulmozyme.
26 Tysabri Biogen IDEC 27 Kogenate FS/ Bayer Helixate FS 28 NovoSeven Novo Nordisk 29 Soliris Alexion 30 Neupogen Amgen 31 Simponi J&J 32 Xolair Roche Genentech & Novartis 33 Stelara J&J 34 Betaseron Bayer 35 Orencia BMS 36 Infanrix GSK 37 Humulin Lilly and Roche 38 Actemra Roche 39 Forteo Lilly 40 Nordi tropin Novo Nordisk 41 Synagis AstraZeneca 42 Yervoy BMS 43 Cerezyme Genzyme 44 BeneFIX Pfizer 45 Cimzia UCB Group 46 Gonal-f Merck KGaA 47 Fluzone Sanofi 48 TNKase Roche Genentech 49 Genotropin Pfizer 50 Xgeva Amgen 51 Lumizyme/ Myozyme Genzyme 52 Synflorix GSK 53 Pulmozyme Roche Genentech 54 Zostavax Merck & Co.
Other products include Activase and TNKase (clot-busters to treat acute heart attacks and strokes), the growth hormone Nutropin, and the pulmonary products Pulmozyme and Xolair.
During the quarter, Genentech completed a Phase III clinical trial of Pulmozyme in early-stage cystic fibrosis.